KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to -$30.1 million.

  • Vertex Pharmaceuticals' Net Cash Flow fell 10474.54% to -$30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$336.6 million, marking a year-over-year increase of 9429.55%. This contributed to the annual value of -$5.8 billion for FY2024, which is 335588.24% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Net Cash Flow is -$30.1 million, which was down 10474.54% from $239.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Net Cash Flow's 5-year high stood at $1.3 billion during Q4 2022, with a 5-year trough of -$4.6 billion in Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Net Cash Flow averaged around -$56.1 million, with its median value being $239.4 million (2025).
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 55809.6% in 2022, then plummeted by 63973.81% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Net Cash Flow stood at $524.8 million in 2021, then soared by 146.61% to $1.3 billion in 2022, then crashed by 159.63% to -$771.7 million in 2023, then grew by 18.54% to -$628.6 million in 2024, then surged by 95.21% to -$30.1 million in 2025.
  • Its Net Cash Flow stands at -$30.1 million for Q3 2025, versus $239.4 million for Q2 2025 and $82.7 million for Q1 2025.